Business
9 Presentations Kick Off Day 1 of the Bionano Symposium 2026 Covering Advances in Optical Genome Mapping for Hematologic Malignancies
SAN DIEGO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced highlights from Day 1 of the Bionano Symposium 2026 entitled Advancements in Hematologic Malignancies with Optical Genome Mapping (OGM). Hematologic malignancies are cancers of the blood and lymph systems. Today’s virtual session brought together global experts and key opinion leaders who shared new data demonstrating how OGM is reshaping cytogenetic and molecular workflows by detecting critical st
About this update from Bionano Genomics, Inc.
[{"type":"image","alt":"Bionano Genomics","displaySize":"","headline":null,"caption":"Bionano Genomics","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":61,"url":"https://media.zenfs.com/en/globenewswire.com/b39fec01655bcf34db9e215be03042b1"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/ylN8_Gs3_qAPxed5dOQIGw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTg1O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/b39fec01655bcf34db9e215be03042b1","width":300,"height":61}},"lazy":false},{"type":"text","content":"SAN DIEGO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced highlights from Day 1 of the Bionano Symposium 2026 entitled Advancements in Hematologic Malignancies with Optical Genome Mapping (OGM). Hematologic malignancies are cancers of the blood and lymph systems. Today’s virtual session brought together global experts and key opinion leaders who shared new data demonstrating how OGM is reshaping cytogenetic and molecular workflows by detecting critical structural variants and accelerating the precision and depth of genomic analysis of leukemias, lymphomas, and multiple myeloma. There are more than 1000 registered attendees from 70 countries across 6 continents for Symposium 2026, making it the single largest event dedicated to OGM and Bionano solutions during the 2026 conference calendar.","length":840,"tagName":"p"},{"type":"text","content":"9 presenters from leading academic medical and cancer centers across Europe and the U.S., including Alka Chaubey, Ph.D., FACMG, Bionano’s chief medical officer showcased how OGM works and how it can deliver enhanced resolution, sensitivity, and comprehensive structural variant detection for clinical research compared with traditional cytogenetic and molecular techniques, including karyotyping (KT), fluorescence in-situ hybridization (FISH), and next-generation sequencing (NGS). They reported high concordance between OGM and traditional cytogenetics methods while emphasizing OGM’s ability to resolve complex rearrangements, identify novel driver events, and rescue cases with failed conventional cytogenetics. Speakers underscored the growing role of OGM as an integrated component of modern hematologic malignancy research, often in combination with next generation sequencing (NGS) and analysis in VIATM software, Bionano’s solution for integra...